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vement disorders (n=2), neuromyelitis optica (n=2),
aseptic meningitis (n=1) were others manifestations
obser ved. Cognitive dysfunction was observed in 3 of
these patients. The frequency of constitutional symp-
toms (such as fever and fatigue) and lung involvement
was significantly higher (p< 0,05) and the articular
symptoms were significantly less frequent (p< 0,05) in
pSS with neurological involvement. The neurologic
outcome was good in 77% of the patients. 
Conclusion: The current study underlines the diversi-
ty of neurologic complications of pSS. The frequency of
neurologic manifestations as first manifestation of pSS,
especially in the event of CNS involvement, could ex-
plain why SS is frequently under diagnosed or late diag-
nosed. Screening for SS should be systematically per-
formed in cases of acute or chronic myelopathy, axonal
sensorimotor neuropathy, or cranial nerve involvement.
Keywords: Neurological Involvement; Primary Sjögren
Syndrome.
rEsUMO
Objectivos: Estudo retrospectivo, transversal caso-con-
trolo para avaliar a prevalência, as manifestações e a
evolução do compromisso neurológico numa coorte de
doentes com Sindrome de Sjogren primário (SSp) de
um único centro. 
Material e Métodos: De um total de 93 doentes com
o diagnóstico de SSp mediante os critérios propostos
por o American–European Consensus Group de 2002, fo-
ram revistos os dados clínicos de todos os doentes com
sintomas neurológicos avaliados na unidade de neu-
roimunologia. Os dados demográficos, clínicos e sero-
imunológicos foram comparados entre os dois grupos
com e sem manifestações neurológicas. 
Resultados: O envolvimento neurológico foi detecta-
do em 26 (28%) dos 93 doentes e precedeu o diagnós-
tico de SSp em 12 (46%) doentes, todos do sexo femi-
nino. A idade média de inicio da doença e do compro-
AbstrAct 
Objectives: To perform an observational retrospective
cross-sectional case-control study to evaluate preva-
lence, clinical patterns and outcomes of neurological
involvement in a cohort of Primary Sjögren Syndrome
(pSS) patients followed up in a single center. 
Material and Methods: From a total of 93 pSS patients,
diagnosed according to the 2002 criteria proposed by
the American-European Consensus Group, we revie-
wed the clinical data of those with neurological com-
plaints that were referred to observation by Neuroim-
munology doctors. Demographic, clinical, seroimmu-
nological data were compared between patients with
and without neurological involvement. 
Results: Neurological involvement was detected in 26
(28%) of the 93 patients. Neurological symptoms pre-
ceded the diagnosis of pSS in 12 (46%) patients. They
were all females. The mean age at disease onset and
neurological onset were 41,2 and 47,9 years, respecti-
vely. Twelve patients (46%) had peripheral system in-
volvement (PNS), 13 (50%) patients had central ner-
vous involvement (CNS) disorders and one (4%) pa-
tient had both PNS and CNS involvement. In patients
with PNS, pure sensory neuropathy (small fiber neu-
ropathy confirmed by quantitative sensory testing and
sural neuropathy) occurred most frequently (n =5), fol-
lowed by cranial nerve involvement affecting trigemi-
nal, facial, or trochlear nerves (n = 4). Multiple mono-
neuropathy (n = 1), sensorimotor polyneuropathy
(n=1), autonomic neuropathy (n=1) and myasthenia
gravis (n = 1), were also observed. In patients with CNS
disorders, headache (n=3) occurred most frequently, in
two patients with MRI abnormalities compatible with
inflammatory disease. Spinal cord involvement (n=2),
seizures (n = 2), motor and sensory deficit (n=2), mo-
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misso neurológico foi de 41.2 e 47.9 anos, respectiva-
mente.  O envolvimento do sistema nervoso periféri-
co (SNP), do sistema nervoso central (SNC) ou ambos
(SNP + SNC) foi registado em 12 (46%), 13 (50%) e 1
(4%) dos doentes, respectivamente, Nos doentes com
compromisso do SNP, a neuropatia sensitiva pura (neu-
ropatia de pequenas fibras confirmada por teste sen-
sorial quantitativo e neuropatia sural) foi a mais fre-
quente (n=5), seguida do compromisso de pares cra-
neanos envolvendo o trigemio, facial ou troclear (n=4).
A mononeuropatia múltipla (n=1) a polineuropatia
sentitivomotora (n=1), a neuropatia autonómica (n=1)
e a miastenia gravis (n=1) foram também observadas.
Nos doentes com atingimento do SNC, a cefaleia foi
um sintoma descrito em 2 doentes com doença infla-
matória identificada por RMN. Outras manifestações
registadas foram: compromisso medular (n=2), con-
vulsões (n=2), défices motores ou sensitivos (n=2),
perturbações do movimento (n=2), neuromielite ópti-
ca (n=2) e meningite asséptica (n=1). Em 3 doentes foi
ainda registada disfunção congnitiva. A presença de
sintomas constitucionais (como febre ou fadiga) e o
envolvimento pulmonar foram mais frequentes 
(p< 0.05) e as manifestações articulares foram menos
frequentes (p<0.05) nos doentes com SSp com envol-
vimento neurológico. O outcome neurológico foi favo-
rável em 77% dos doentes. 
Conclusão: Este estudo enfatiza a diversidade de ma-
nifestações neurológicas no SSp. A frequência de mani-
festações neurológicas como primeira manifestação do
SSp, particularmente no caso do envolvimento do SNC,
poderá explicar o atraso no diagnóstico do SS ou a ra-
zão porque é frequentemente subdiagnosticado. O ras-
treio clínico de SS deveria ser preconizado de forma sis-
temática nos casos de mielopatia aguda ou crónica, neu-
ropatia sensitivomotora axonal ou de pares craneanos.
Palavras-Chave: Compromisso Neurológico; Síndro-
me de Sjögren Primário.
intrOdUctiOn
Primary Sjögren Syndrome (pSS) is an autoimmune
disorder characterized by a chronic lymphocytic and
plasmacellular infiltration of exocrine glands and ex-
traglandular features including both peripheral ner-
vous system (PNS) and central nervous system (CNS)
involvement1.
Prevalence of neurological manifestations in pSS va-
ries between 10 and 60%. The wide range is in part
due to an evolving definition of Sjogren’s syndrome
(prior to the 2002 case definition), as well as differen-
ces in study populations, and in definition or methods
of detection of neuropathy2,3.
The pathogenic mechanisms responsible for most
forms of neurological involvement in pSS are unk-
nown. Several mechanisms are suggested for the deve-
lopment of the involvement of PNS in pSS patients.
Vascular or peripheral inflammatory infiltrates with or
without necrosis may be found. Vasculitis of the vasa
nervorum has also been proposed as pathogenic me-
chanism in PNS involvement2,6. 
Three pathogenic factors may explain the CNS di-
sorders. The first hypothesis is the direct infiltration of
the CNS by mononuclear cells; the second hypothe sis
is the vascular involvement. The vascular injury may be
related to the presence of antineuronal antibodies and
anti-Ro antibodies. Other authors suggest that the un-
derlying mechanism of CNS lesion in pSS is the ische-
mia secondary to small vessel vasculitis2, 6-9. 
Pure or predominantly sensory polyneuropathies are
the most common neurologic manifestation (e.g. sen-
sory ataxic or small fiber sensory painful neuropathy)2,4.
Mononeuropathy multiplex, polyradiculopathy, symp-
tomatic dysautonomia, cranial neuropathy, myopathy,
and central nervous system involvement are less com-
mon. pSS associated sensory neuropathy is often the
presenting feature of Sjogren’s syndrome and, therefo-
re, a high index of suspicion is required, particularly in
female patients with nonlength-dependent, painful, or
ataxic sensory neuropathy or those with trigeminal sen-
sory and autonomic involvement8-10.
The aim of the study was to describe the prevalence, cli-
nical patterns and outcomes of neurological involvement
in a cohort of pSS patients followed up in a single center.
MAtEriAls And MEthOds
PAtiEnts And cOntrOls
This observational retrospective cross-sectional
case–control study included all patients with pSS diag-
nosis followed up in Neurology Department and Cli-
nical Immunology Unit of our center.
These patients were diagnosed as having pSS on the
basis of the revised version of the European criteria pro-
posed by the American-European Consensus Group3.
Patients with an overlapping syndrome such as rheu-
matoid arthritis, systemic lupus erythematosus, or sys-
temic sclerosis were excluded. Clinical data were ob-
tained from medical records. The duration of data col-
lection was 3 months.
Demographic, clinical, immunological data were
compared between patients with and without neuro-
logical involvement.
Fever was defined as higher than 38.0°C, and the
positivity of antinuclear antibody (ANA) was defined
as a titer superior to 1/160 by the indirect immuno-
fluorescence method or ELISA method. 
clAssificAtiOn Of nEUrOlOgicAl invOlvEMEnt
Neurological involvement, and classification of the two
subsets PNS an CNS, was assessed by neurological exa-
mination, peripheral nerve conduction study (NCS)
with quantitative sensory testing (QST), magnetic re-
sonance imaging (MRI), electroencephalogram (EEG),
and cerebrospinal fluid (CSF). Manifestations were ca-
tegorized as reported in Table I.
nEUrOlOgic OUtcOME
Clinical outcome was assessed using the Modified Ox-
ford Handicap Scale (MOHS)4,5:
• 0 = No symptoms.
• 1 = Minor symptoms not interfering with lifestyle.
• 2 = Minor handicap with symptoms leading to some
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restriction in lifestyle but not interfering with the
patient’s capacity to look after himself or herself.
• 3 = Moderate handicap with symptoms that signi-
ficantly restrict lifestyle and prevent totally inde-
pendent existence.
• 4 = Moderately severe handicap with symptoms that
clearly prevent independent existence though not
needing constant attention.
• 5 = Severe handicap leading to total dependence and
requiring constant attention during night and day.
• 6 = Death.
stAtisticAl AnAlysis
Statistical analyses were performed using the Fisher
exact test and student T test for categorical and conti-
nuous variables, respectively. The data were analyzed
with SPSS 17.1 software. A value of P<0.05 was con-
sidered to indicate statistical significant
rEsUlts
cOMPArisOn Of clinicAl MAnifEstAtiOns 
bEtwEEn PAtiEnts with And withOUt 
nEUrOlOgicAl invOlvEMEnt in Pss 
As shown in Table II, 93 patients with pSS were en-
tAblE i. sPEctrUM Of cns And Pns invOlvEMEnt in Pss
CNS PNS
Focal Sensory neuropathy
Motor and/or sensory deficit Small fiber neuropathy
Aphasia/dysarthria Sensory ataxic neuropathy
Seizure disorders Sensorimotor polyneuropathy
Brainstem syndrome Polyradiculopathy
Cerebellar syndrome Multiple mononeuropathy
Diffuse Autonomic neuropathy
Acute or subacute encephalopathy Cranial neuropathies
Aseptic meningitis Myasthenia gravis 
Cognitive dysfunction/dementia 
Movement disorders
Spinal Cord Dysfunction
Transverse myelitis
Chronic progressive myelitis
Lower motor neuron disease
Other
Neuromyelitis optica
Multiple sclerosis-like disease
rolled in this study, including 26 patients with neuro-
logical involvement that were all female. The age at
diagnosis with pSS was 41,2 ± 18.4 years (mean ± SD)
and 45.8±13.3 years (mean ± SD) in patients with and 
without neurological involvement, respectively. 
The disease duration was defined as years between
onset of sicca symptoms and the time of data collection
from medical records. The median duration was 11,7
years and 11, 15 years in the PNS/ CNS and non-
-PNS/CNS groups, respectively. 
Neurologic involvement frequently preceded the
diagnosis of pSS in 12 (46%) patients. Twelve patients
(46%) had peripheral system involvement PNS, 13
(50%) patients had CNS disorders and one (4%) pa-
tients had both PNS and CNS involvement.
The frequency of constitutional symptoms (such as
fever and fatigue), lung involvement and articular
symptoms was 19 (20%), 8 (9%) and 11 (12%) in the
PNS/CNS group and 10 (11%), 2 (2,1%) and 46 (49%)
in the non-PNS/CNS group, respectively.
The frequency of constitutional symptoms and lung
involvement was significantly higher (p< 0,05) and the
articular symptoms were significantly less frequent 
(p< 0,05) in pSS with neurological involvement. The-
re was no statistical significant difference between the
two groups in involvement of other organs or systems,
including cardiovascular, endocrine, gastrointestinal,
renal and skin involvement. 
nEUrOlOgicAl findings in Pss PAtiEnts with
Pns invOlvEMEnt
PNS findings included five patients with sensorial neu-
ropathy and four patients with cranial neuropathy.
Multiple mononeuropathy, sensorimotor polyneuro-
pathy and autonomic neuropathy were observed each
in one patient (Table III). There was also one patient
with myasthenia gravis (generalized with positive anti-
acetylcholine receptors antibodies) that was conside-
red to have this disease associated with pSS.
Five patients with sensorial neuropathy included
three with small fiber neuropathy and two with sural
neuropathy. Four patients with cranial neuropathy in-
cluded two with facial nerve palsy, one with trigemi-
ÓRGÃO OfICIAL dA SOCIEdAdE PORTUGUESA dE REUMATOLOGIA
32
Primary Sjögren’S Syndröme
tAblE iii. nEUrOlOgicAl findings in Pss
PAtiEnts with Pns invOlvEMEnt
N
Sensorial neuropathy 5
– small fiber neuropathy 3
– sural neuropathy 2
Cranial neuropathy 4
– facial nerve palsy 2
– trigeminal neuralgia 1
– abducens nerve palsy 1
Multiple mononeuropathy 1
Sensorimotor polyneuropathy 1
Autonomic neuropathy 1
Myasthenia gravis 1
Total 13
tAblE iv. nEUrOlOgicAl findings in Pss
PAtiEnts with cns invOlvEMEnt
N
Headache with MRI abnormalities 2
compatible with inflammatory disease
– migraine with visual aura 2
Tension-type headache 1
Spinal cord involvement 2
Seizures 2
Motor and sensory deficits 2
Movement disorders 2
Neuromyelitis optica 2
Aseptic meningitis 1
Total 14
tAblE ii. cOMPArisOn Of clinicAl fEAtUrEs bEtwEEn Pns/cns grOUP And nOn-Pns/cns grOUP
All PNS/CNS Non-PNS/CNS P value
Ratio ♀:♂ 90♀:3♂ 26♀ 64♀:3♂ _
Number 93 26 67
Age at onset symptoms 44,2 41,8 45,8 p = 0,698
Age at diagnosis 47,6 45,1 48,7 p = 0,767
Duration  (years) 11,4 11,7 11,15 p = 0,934
nal neuralgia, one with abducens nerve palsy.
The nerve conduction velocity studies showed ab-
sence of the sensory action potential in two patients
with sural neuropathy, increase of the threshold of sen-
sitivity to cold in two patients with small fiber neuro-
pathy. The others findings were reduction in amplitu-
de of sural and peroneal nerves in patients with mo-
noneuritis multiplex and axonal sensory polyneuro-
pathy asymmetric in patients with sensorimotor
polyneuropathy.
nEUrOlOgicAl findings in Pss PAtiEnts with
cns invOlvEMEnt
As shown in Table IV, CNS findings included three
with headache, two patients with migraine with visual
aura, which have MRI abnormalities compatible with
inflammatory disease; and one patient with tension-
type headache.
Two patients presented optic neuritis with a tetra-
piramidal syndrome and a posterior columns syndro-
me. Both were positive for anti- Aquaporin4 (AQ4) an-
tibodies. Spinal cord MRI showed an extensive cen-
tro-medular lesion from C2 to C5 in one patient and
from C2 to C7 in another patient. Brain MRIs were
normal. These patients were diagnosed as having neu-
romyelitis optica associated with pSS.
The spinal cord involvement was observed in two
patients, one with transverse myelitis with CFS with
increased protein level and cell count, and other with
chronic progressive myelopathy with progressive spas-
tic paraparesis and urinary disorders. This patient had
progressive worsening, developed a dementia syndro-
me and died nine years later. Brain MRIs showed mul-
tiple, some confluent, small hiperintense lesions in the
supratentorial white matter, mainly subcortical and
posterior. The one that developed a dementia syndro-
me also had a cortico-subcortical diffuse atrophy. Spi-
nal cord MRIs were normal. 
There were two cases of epilepsy with complex par-
tial seizures, which started at 23 and 66 years old. Neu-
rological examinations were normal. MRIs showed on
the first a gliotic focus of unspecific nature in right
frontal subcortical white matter and on the second
multiple T2 hyperintense lesions in the periventricu-
lar white matter, semioval centers, left thalamus and
right cerebellar hemisphere. EEGs showed paroxistic
activity anterior and lateral bilaterally, with generalized
paroxysmal activity with spikes and waves during the
seizures.CSF analysis was normal and NMDA-antibo-
dies were negative
Two patients had motor and sensory deficits. One at
40 years suddenly had left hemiparesis and dysesthesia
that disappeared gradually in 2 months. Brain MRI was
normal. The other was referred to neurology by gene-
ralized weakness since 64 years old and presented with
a slight tetraparesis with brisk reflexes and episodes of
dizziness. Brain MRI showed multiple hyperintense le-
sions on the basal ganglia, corpus callosum and pons. 
In two patients was observed movement disorders
secondary to pSS, one with clinical features of atypi-
cal Parkinsonism with a symmetric akinetic/rigid syn-
drome, gait disorder, and postural instability, without
prominent tremor. In this patints brain MRIs showed
multiple focal lesions scattered in the subcortical and
deep white matter of nonspecific nature, probably glio-
tic/ischemic. Another patient has a clinical picture
more closely resembling idiopathic Parkinson’s disea-
se (PD), with asymmetric tremor and bradykinesia.
CSF exams were normal. A lack of response to L-dopa
was observed in the two cases, arguing against the
diagnosis of idiopathic PD.
One patient had a clinical picture of subacute afe-
brile aseptic meningitis (AM) as neurological manifes-
tation of pSS, as initial manifestation of disease. The
neurological symptomatology presented gradual on-
set and progression of mild headache, neck rigidity
and diplopia. CSF analysis showed moderate lym -
phocytosis and increased protein level but no eviden-
ce of immunoglobulin intrathecal synthesis. Three bo-
lus of intravenous steroid therapy led to a complete di-
sappearance of the neurological symptomatology and
to normalization of the CSF inflammatory pattern.
Spinal Cord or brain MRI was not performed in
three patients: the patient with aseptic meningitis, the
one with tension-type headache and the other patient
with movement disorder.
During the follow-up, one patient with spinal cord
involvement and others two with movement disorder
and the headache (tension-type headache) developed
cognitive dysfunction with criteria for dementia. One
patient whose initial manifestation was the cranial neu-
ropathy during the follow-up had CNS involvement
(migraine with visual aura with brain MRI abnormali-
ties compatible with inflammatory disease). The re-
maining 21 patients had no other neurological mani-
festations secondary to SSp.
According to Modified Oxford Handicap Scale4,5,
the neurologic outcome was good in all patients with
PNS involvement. The patient with transverse myeli-
tis had a severe handicap leading to total dependence
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and the patient with chronic progressive myelopathy
died. The patients with movement disorder and hea-
dache that developed cognitive dysfunction also had
an unfavorable evolution of disease with moderate
handicap. 
Fifteen patients were treated with corticosteroids,
resulting in a durable neurologic amelioration or sta-
bilization in 12 cases. This treatment was totally inef-
fective in three patients, those with spinal cord invol-
vement and in other patient with multiple mononeu-
ropathy. Eight patients received immunosuppressive
therapy, including cyclophosphamide in three patients.
It resulted in a partial recovery or stabilization in two
of the four treated patients. In one patient with spinal
cord involvement and other with multiple mononeu-
ropathy, cyclophosphamide was ineffective. Nine pa-
tients received only symptomatic treatment, including
antiepileptic, antiparkinsonian drugs and pyridostig-
mine for myasthenia gravis. 
discUssiOn
Our results showed that neurological complications
were present in 26 (28%) patients, all females. This
study underlines the diversity of neurologic manifes-
tations of pSS and suggests that the frequency of CNS
involvement is similar to that of PNS involvement. This
result is quite different from previous studies, where
PNS involvement was mainly described2,6,11. 
With regard to clinical features, the frequency of
constitutional symptoms and pulmonary involvement
was significantly higher in patients with pSS with neu-
rological complications.
The current study agrees with those of Deland et al,
Mellgren et al and Lafitte et al, who described many ca-
ses (between 47-53%), of pSS with neurologic mani-
festations as presenting symptoms11-13. The absence of
sicca symptoms in 46% of our patients at the onset of
neurologic signs, especially in cases of CNS involve-
ment, emphasizes the difficulty of the diagnosis and
the utility of systematically screening for SS in patients
with neurologic symptoms such as sensory motor axo-
nal polyneuropathy, pure sensory neuropathy, cranial
nerve involvement (especially cochlear and trigeminal
nerves), acute or chronic myelopathy, or multifocal
CNS involvement with onset after 50 years of age2,9.
Our study confirms that peripheral neuropathy is
the commonest PNS complication in pSS, mainly the
sensorial neuropathy. Our series include the main ty-
pes of neuropathy already described in pSS. Small fi-
ber neuropathy (SFN) is a neurological manifestation
of pSS recently describe and the most published series
there is no reference to this manifestation12,13.
SFN is a polyneuropathy selectively involving small-
-diameter myelinated (A-delta) and non-myelinated (C)
nerve fibers and leaving large myelinated fibers relatively
unaffected. Clinical manifestations were mainly distal
burning sensation, dysesthesia, prickling, and allody-
nia, localized in both hands and feet without muscle
weakness and decreasing of the deep tendon reflex6,16-17.
A peripheral nerve conduction study (NCS) usual-
ly reveals normal findings in SFN; however, SFN is oc-
casionally complicated with autonomic nervous failu-
re13. In our study SFN was confirmed by quantitative
sensory testing in two patients. 
Whereas the trigeminal nerve seems to have been
more frequently involved in previous studies, we
found a more frequent involvement of the facial nerve
palsy14,18.
In our cohort, as in other series, the CNS involve-
ment was most frequently focal. Only one series (Mas-
sara et al) have found a slight predominance of diffu-
se neurological pictures, especially a subacute ence -
phalopathy19. 
Unlike other series, in which no cases of NMO is
reported (there are only reports of isolated clinical ca-
ses), in our series we had two cases of this clinical pic-
ture. This can be explained by the fact that NMO pre-
viously had been considered as one component of the
spectrum of complications associated with MS. Ho-
wever, NMO recently has been considered a different
entity from MS, after the discovery of the antibody
anti-AQP4. NMO was classically described as optic
neuritis and longitudinal extensive transverse myelitis,
and is frequently associated to autoimmune disorders
such as thyroiditis, systemic lupus erythematosus
(SLE), or pSS in 10–40% of patients6, 20-21.
With the recent discovery of an antibody anti-AQP4
(NMO-IgG), which is considered to be specific for neu-
romyelitis optica, an overlap between patients with
primary SS and neuromyelitis optica spectrum disea-
ses (NMOSD) is being noted, but there are few studies
that have attempted to address the relationship bet-
ween SS and NMOSD4,19.
In the present study, anti-AQ4 antibody was detec-
ted in two patients with optic neuritis and myelitis and
the diagnosis of NMO was made. If optic neuritis or
multiple lesions in the spinal cord and white matter
are found in pSS patients, anti-AQ4 antibody should
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be screened20-22.
Movement disorders such as tremor, dystonia, and
pseudoathetosis have rarely been reported such neu-
rologic manifestation of pSS. Eleven cases of parkin-
sonism associated with pSS have been published to
date. In our series we describe two cases of a move-
ment disorder associated with pSS23, 24.
Lafitte et al found a high frequency of cognitive dys-
function during pSS. We cannot confirm this finding
because we did not systematically screen patients for
cognitive impairment. However, in 3 patients we con-
firmed cognitive profile with subcortical dysfunction11,13.
MS-like syndromes could represent a particular
subset of neurological involvement, which may heavi-
ly affect outcome. Other series reported high frequen-
cy this picture. In our series we didn’t find any event
MS-like2,19. 
The differential diagnosis between pSS with MS-like
features and classical MS may be very difficult, since a
sicca syndrome and a number of autoantibodies may
also be found in the latter condition. The presence of
extraglandular manifestations, antibodies against alfa-
fodrin more frequently detectable in pSS and some
MRI features may be useful for the differential diagnosis19.
The role of brain MRI in the assessment of CNS-pSS
has not yet been fully defined. Diffuse, small and punc-
tuate white matter hyperintensities (WMHs) represent
a frequent but a unspecific finding with increasing pre-
valence with ageing, diabetes, atherosclerosis and hy-
pertension. Multiple WMHs have been detected in up
to 80% of patients with pSS and focal progressive neu-
rological dysfunctions and also in 50% of patients with
a diffuse pattern19,25. These abnormalities have been
more frequently reported in asymptomatic pSS patients
than in age- and sex-matched healthy subjects25-27. 
In our series, the main differences regarding extra-
glandular manifestations between PNS/CNS-pSS and
non-PNS/CNS-pSS patients were related to constitu-
tional symptoms, lung and articular involvement. The
frequency of constitutional symptoms and lung invol-
vement was significantly higher in pSS with neurolo-
gical involvement than in pSS without neurological in-
volvement and the articular symptoms were signifi-
cantly less frequent in pSS with neurological involve-
ment. The meaning of these associations is unclear.
However, the fact that the articular symptoms were
less frequent in patients with neurological involve-
ment, may explain the low prevalence of neurological
involvement in series of patients from rheumatology
departments28.
In our study, severe disability was more frequent in
cases of CNS involvement than in cases of PNS invol-
vement, suggesting the need for intensive and early
treatment in cases of CNS involvement.
cOnclUsiOn
In conclusion, our findings remark the great hetero-
geneity of neurological involvement in pSS, which re-
presents a not negligible complication of the disease. 
A lower prevalence of neurological complications
was reported in other series. Maybe it was due to mis-
sed diagnosis or different methodologies. In our co-
hort, the CNS involvement had similar frequency to
PNS involvement. This result is quite different from
that of previous studies where PNS involvement was
mainly described. 
The association between lung involvement, consti-
tutional symptoms and neurological complications de-
serves attention but needs further confirmations in
prospective studies. As it happened with lupus patients
in which the availability of a normative classification
of neuropsychiatric syndromes boosted the research
in this field, we strongly advise, in the near future, a si-
milar multidisciplinary and international multicentre
effort for pSS.
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